| 摘要 |
The present invention relates to novel tetralin ER-βagonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-βmediated disease such as nocturia, obstructive uropathy, benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon cancer, prostate cancer, infertility, depression, leukemia, inflammatory bowel disease, and arthritis.
|
